The U.S. Food and Drug Administration has amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine, authorizing the use of a booster dose for 16-and-17-year olds at least six months after completion of the primary vaccine.
FDA approves Pfizer booster for 16- and 17-year-olds
